Kura Oncology and Kyowa Kirin Announce FDA Acceptance of New Drug Application for Ziftomenib in Relapsed or Refractory AML with NPM1 Mutation
2/6 01:10
Kura Oncology and Kyowa Kirin announce FDA acceptance of ziftomenib NDA for relapsed/refractory AML, targeting a November 2025 decision....